Table 2.

Univariate and multivariate analyses of cancer-free survival using the cox proportional-hazard regression. CI, Confidence Interval; HR, Hazard Ratio; TIL, Tumor Infiltrating Lymphocytes; PSA, Proportionated Stromal Area; ISP, Immature Stromal Percentage; Myxoid Stromal Ratio; MMR, Mis-match repair; KRAS, Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF, B-Raf Proto-Oncogene. Significant features (p≤0.05) are shown in bold.

Variable	Frequency	Univariate HR	CI	p value	Multivariate HR	CI	p value
Age		0.987	0.943–1.032	0.560	1.051	0.982–1.125	0.151
<=65	22 (36.67%)
>65	38 (63.33%)
Gender		1.247	0.429–3.624	0.685	1.489	0.476–4.652	0.494
Male	36 (60%)
Female	24 (40%)
Tumor budding		2.815	0.784–10.10	0.112	1.011	0.01–7.83	0.173
TBD1	24 (40%)
TBD2 or TBD3	36 (60%)
Pathological stage		3.705	1.015–13.53	0.047	0.405	0.140–1.170	0.095
≤PT2	13 (21.67%)
PT3–PT4	47 (78.33%)
TIL		0.404	0.111–1.467	0.168	0.120	0.018–0.809	0.029
Low	40 (66.67%)
High	20 (33.33%)
Lymph node stage		0.577	0.180–1.848	0.355	0.909	0.205–4.033	0.900
N0	32 (53.33%)
N1–N2	28 (46.67%)
PSA		21.739	2.829–170.7	0.003	7.69	2.217–100.0	0.018
>=0.9	25 (41.67%)
<0.9	35 (58.33%)
ISP		1.189	1.106–1.278	<0.001	1.253	1.078–1.458	0.003
<10	37 (61.67%)
>=10	23 (38.33%)
MSR		5.613	1.947–16.19	0.028	7.194	1.197–43.70	0.030
<0.19	39 (65%)
>0.19	21 (35%)
Tumor grade		2.815	0.784–10.10	0.112	1.454	0.300–7.043	0.642
G1	44 (73.33%)
G2–G3	16 (26.67%)
Stromal differentiation		3.715	1.829–16.64	0.048	1.230	1.035–1.462	0.019
Mature	27 (45%)
Immature/intermediate	33 (55%)
MMR		2.607	0.903–7.526	0.076	0.456	0.0533–3.958	0.477
Intact	46 (76.67%)
Loss	14 (23.33%)
KRAS		2.828	0.17–47.146	0.469
Wild type	8 (66.67%)
Mutation	4 (33.33%)
BRAF		1.31	0.11–3.52	0.97
Wild type	8 (88.89%)
Mutation	1 (11.11%)